Mechanisms of cancer metastasis: Involvement of cancer stem cells?

Minerva Medica

Volumn 101, Issue 3, 2010, Pages 179-191

  Ratajczak, M ^a,b   Tarnowski, M ^a   Staniszewska, M ^b   Sroczynski, T ^b   Banach, B ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Neoplasm metastasis; Neoplastic stem cells; Stem cells

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CHORIONIC GONADOTROPIN BETA SUBUNIT; ETODOLAC; FIBROBLAST GROWTH FACTOR; HEPARIN; IMATINIB; MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; PLERIXAFOR; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; T 140;

ANGIOGENESIS; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL TRANSFORMATION; COMPLEMENT SYSTEM; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; METASTASIS; MUTATION; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; TUMOR GROWTH; VERY SMALL EMBRYONIC LIKE STEM CELL;

ADULT; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CHEMOKINES; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIOTHERAPY; RECEPTORS, CXCR;

EID: 77956407722     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Uehara Y, Kitamura N. Expression of a human hepatocyte growth factor/scatter factor cDNA in MDCK epithelial cells influences cell morphology, motility, and anchorage-independent growth. J Cell Biol 1992;117:889-94.
2. Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP. Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 1989;109(4 Pt 1):1495-509.
3. Greenburg G, Hay ED. Cytodifferentiation and tissue phenotype change during transformation of embryonic lens epithelium to mesenchyme-like cells in vitro. Dev Biol 1986;115:363-79.
4. Li Y, Joseph A, Bhargava MM, Rosen EM, Nakamura T, Goldberg I. Effect of scatter factor and hepatocyte growth factor on motility and morphology of MDCK cells. In Vitro Cell Dev Biol 1992;28A:364-8.
5. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993;121:145-54.
6. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 2007;24:587-97. (Pubitemid 50000849)
7. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
8. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
9. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
10. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009;1176:154-69.
11. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays 2009;31:1038-49.
12. Scadden DT. The stem-cell niche as an entity of action. Nature 2006;441:1075-9.
13. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007;1:607-11.
14. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the "soil" for breast cancer metastasis: the pre-metastatic niche. Breast Dis 2006;26:65-74.
15. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1: 313-23.
16. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
17. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009;69:1776-81.
18. Hassan HT, Zhai X, Goodacre JA. CD133 stem cells in adult human brain. J Neurooncol 2008;89:247-248; author reply 249.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
20. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67:4827-33.
21. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 2009;33:175-81.
22. She JJ, Zhang PG, Wang ZM, Gan WM, Che XM. Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther 2008;7:1663-8.
23. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
24. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-71.
25. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37.
26. Welm B, Behbod F, Goodell MA, Rosen JM. Isolation and characterization of functional mammary gland stem cells. Cell Prolif 2003;36(Suppl 1):17-32. (Pubitemid 37521841)
27. Ratajczak MZ, Zuba-Surma EK, Machalinski B, Ratajczak J, Kucia M. Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev 2008;4:89-99.
28. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 2008;215:287-91.
29. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
30. Ratajczak MZ, Shin DM, Kucia M. Very small embryonic/epiblast-like stem cells: a missing link to support the germ line hypothesis of cancer development? Am J Pathol 2009;174:1985-92.
31. Hotakainen K, Ljungberg B, Haglund C, Nordling S, Paju A, Stenman UH. Expression of the free beta-subunit of human chorionic gonadotropin in renal cell carcinoma: prognostic study on tissue and serum. Int J Cancer 2003;104:631-5.
32. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004;101:2006-10. (Pubitemid 39425376)
33. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-l(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006;20:857-69.
34. Zuba-Surma EK, Kucia M, Wu W, Klich I, Lillard JWJr, Ratajczak J et al. Very small embryonic-like stem cells are present in adult murine organs: ImageStream-based morphological analysis and distribution studies. Cytometry A 2008;73A:1116-27.
35. Shin DM, Zuba-Surma EK, Wu W, Ratajczak J, Wysoczynski M, Ratajczak MZ, Kucia M. Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia 2009;23:2042-51.
36. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007;185:7-19.
37. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40.
38. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 2002;1:68-78.
39. Dow LE, Humbert PO. Polarity regulators and the control of epithelial architecture, cell migration, and tumorigenesis. Int Rev Cytol 2007;262:253-302.
40. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999;43(Suppl).S3-10.
41. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997;80(8 Suppl): 1529-37.
42. Christofen G. New signals from the invasive front. Nature 2006;441:444-50.
43. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
44. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
45. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005;106:1901-10.
46. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-8.
47. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999;10:463-71. (Pubitemid 29205482)
48. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005;105:3793-801.
49. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23:879-94.
50. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, Chemotaxis, and adhesion. Blood 2002;100:2597-606.
51. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005;24:4462-71.
52. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006;20:1915-24.
53. Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Kodama R, Sanke T et al. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008;8:340.
54. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13.
55. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280:35760-6.
56. Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer 2010 [Epub ahead of print].
57. Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J et al. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010;8:1-14.
58. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998;187:2009-21.
59. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCLlO, in human breast adenocarcinoma cell lines. Immunol Lett 2004;92:171-8.
60. Robledo MM, Bartolome RA, Longo N, Rodriguez-Frade JM, Mellado M, Longo I et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-105.
61. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007;26:4679-88.
62. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998;28:3696-705. (Pubitemid 28510780)
63. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003;278:289-95.
64. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82.
65. Xie Q, Liu KD, Hu MY, Zhou K. SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 2001;7:816-20. (Pubitemid 34051499)
66. Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003,63:7926-35.
67. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IY et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997;15:2093-108.
68. Bar-Eli M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997;173:275-8.
69. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005;438:820-7.
70. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75. (Pubitemid 44835111)
71. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008;10:1349-55.
72. Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004;95:1191-9.
73. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
74. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-30.
75. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000;96:1789-97. (Pubitemid 30661063)
76. Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992;18:392-415.
77. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005;113:752-60.
78. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006;46: 1199-209.
79. Wysoczynski M, Kucia M, Ratajczak J, Ratajczak MZ. Cleavage fragments of the third complement component (C3) enhance stromal derived factor-1 (SDF-1)-mediated platelet production during reactive postbleeding thrombocytosis. Leukemia 2007;21: 973-82.
80. Schraufstatter IU, Discipio RG, Zhao M, Khaldoyanidi SK. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol 2009;182:3827-36.
81. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101: 2999-3004.
82. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
83. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
84. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008;10:788-801.
85. Salvi A, Sabelli C, Moncini S, Venturin M, Arid B, Riva P et al. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBSJ 2009;276:2966-82.
86. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-6.
87. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007;13:1172-8. (Pubitemid 47080461)
88. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 2008;582:3663-8.
89. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008;373:607-12.
90. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-52.
91. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004;3:29-37.
92. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102.
93. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003,94:321-7.
94. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006;103:5090-5.
95. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoredurtive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
96. Takahashi-Yanaga F, Yoshihara T, Jingushi K, Miwa Y, Morimoto S, Hirata M et al. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochem Biophys Res Commun 2008;377: 1185-90.
97. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A et al. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 2007;46:849-57.
98. Rao AS, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J et al. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 2006;91:159-68.
99. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007;33:688-94. (Pubitemid 350157013)
100. Iiizumi M, Liu W, Pai SK, Funita E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 2008;1786:87-104.